Cited by 273Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer

Open access
Freed-Pastor, William A., Lambert, Laurens J., Ely, Zackery A., Pattada, Nimisha B., Bhutkar, Arjun, Eng, George, Mercer, Kim L., Garcia, Ana P. +16 more·2021·Cancer Cell

Abstract

The CD155/TIGIT axis can be co-opted during immune evasion in chronic viral infections and cancer. Pancreatic adenocarcinoma (PDAC) is a highly lethal malignancy, and immune-based strategies to combat this disease have been largely unsuccessful to date. We corroborate prior reports that a substantial portion of PDAC harbors predicted high-affinity MHC class I-restricted neoepitopes and extend these findings to advanced/metastatic disease. Using multiple preclinical models of neoantigen-expressing PDAC, we demonstrate that intratumoral neoantigen-specific CD8+ T cells adopt multiple states of dysfunction, resembling those in tumor-infiltrating lymphocytes of PDAC patients. Mechanistically, genetic and/or pharmacologic modulation of the CD155/TIGIT axis was sufficient to promote immune evasion in autochthonous neoantigen-expressing PDAC. Finally, we demonstrate that the CD155/TIGIT axis is critical in maintaining immune evasion in PDAC and uncover a combination immunotherapy (TIGIT/PD-1 co-blockade plus CD40 agonism) that elicits profound anti-tumor responses in preclinical models, now poised for clinical evaluation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.07.007

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A combination of scRNA-seq, multiplex IHC, and CyTOF immune profiling showed an inverse relationship between suppressive myeloid populations and CD8 effector T cell infiltration.

    “For example, combined scRNA-seq, multiplex IHC, and CyTOF immune profiling demonstrated an inverse correlation between suppressive myeloid populations and CD8 effector T cell infiltrations277.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [277]

  • The same analyses found signs of systemic CD8 T cell exhaustion, and network analysis pointed to TIGIT as a central immune-suppression node.

    “These further identified that CD8 T cells show indications of systemic exhaustion, and a network analysis of potential checkpoint receptor-ligand pairing suggested TIGIT as a key node of immune-suppression.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [277]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Freed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., Hwang, W. L., Schenkel, J. M., Jaeger, A. M., Bronson, R. T., Westcott, P. M. K., Hether, T. D., Divakar, P., Reeves, J. W., Deshpande, V., Delorey, T., Phillips, D., Yilmaz, O. H., Regev, A., & Jacks, T.
Affiliations
  • Harvard University (US)
  • Koch Institute for Integrative Cancer Research At MIT (US)
  • Massachusetts General Hospital (US)
  • Broad Institute (US)
  • Brigham and Women's Hospital (US)
  • Nanostring Technologies (United States) (US)
Corresponding author
Jacks, Tyler
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-10
Volume
39
Issue
10
Pages
1342-1360.e14
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3189337473
Cited by
273
References
124
Citations by year
2026: 42 · 2025: 58 · 2024: 50 · 2023: 70 · 2022: 45 · 2021: 7 · 2013: 1
FWCI
15.73
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion)
  • SSRN Electronic Journal (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
Funders
  • American Association for Cancer Research
  • National Cancer Institute (P30-CA14051)
  • Damon Runyon Cancer Research Foundation
  • National Institutes of Health (T32GM007287)
  • Howard Hughes Medical Institute
  • Entertainment Industry Foundation
  • Stand up to Cancer
  • Broad Institute
  • Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
  • Johnson and Johnson
  • Lustgarten Foundation
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
CD155, TIGIT, pancreatic ductal adenocarcinoma, immune evasion, neoantigens, CD8+ T cell dysfunction, CD40 agonism, combination immunotherapy, tumor-infiltrating lymphocytes
MeSH terms
Animals, Humans, Immunotherapy, Pancreatic Neoplasms, Receptors, Virus, Lymphocytes, Tumor-Infiltrating, Mice, Immune Evasion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review